Pertwee R G, Thomas A, Stevenson L A, Ross R A, Varvel S A, Lichtman A H, Martin B R, Razdan R K
School of Medical Sciences, Institute of Medical Sciences, University of Aberdeen, Aberdeen, UK.
Br J Pharmacol. 2007 Mar;150(5):586-94. doi: 10.1038/sj.bjp.0707124. Epub 2007 Jan 22.
To follow up in vitro evidence that Delta(9)-tetrahydrocannabivarin extracted from cannabis (eDelta(9)-THCV) is a CB(1) receptor antagonist by establishing whether synthetic Delta(9)-tetrahydrocannabivarin (O-4394) and Delta(8)-tetrahydrocannabivarin (O-4395) behave as CB(1) antagonists in vivo.
O-4394 and O-4395 were compared with eDelta(9)-THCV as displacers of [(3)H]-CP55940 from specific CB(1) binding sites on mouse brain membranes and as antagonists of CP55940 in [(35)S]GTPgammaS binding assays performed with mouse brain membranes and of R-(+)-WIN55212 in mouse isolated vasa deferentia. Their ability to antagonize in vivo effects of 3 or 10 mg kg(-1) (i.v.) Delta(9)-tetrahydrocannabinol in mice was then investigated.
O-4394 and O-4395 exhibited similar potencies to eDelta(9)-THCV as displacers of [(3)H]-CP55940 (K (i)=46.6 and 64.4 nM, respectively) and as antagonists of CP55940 in the [(35)S]GTPgammaS binding assay (apparent K (B)=82.1 and 125.9 nM, respectively) and R-(+)-WIN55212 in the vas deferens (apparent K (B)=4.8 and 3.9 nM respectively). At i.v. doses of 0.1, 0.3, 1.0 and/or 3 mg kg(-1) O-4394 and O-4395 attenuated Delta(9)-tetrahydrocannabinol-induced anti-nociception (tail-flick test) and hypothermia (rectal temperature). O-4395 but not O-4394 also antagonized Delta(9)-tetrahydrocannabinol-induced ring immobility. By themselves, O-4395 and O-4394 induced ring immobility at 3 or 10 mg kg(-1) (i.v.) and antinociception at doses above 10 mg kg(-1) (i.v.). O-4395 also induced hypothermia at 3 mg kg(-1) (i.v.) and above.
O-4394 and O-4395 exhibit similar in vitro potencies to eDelta(9)-THCV as CB(1) receptor ligands and as antagonists of cannabinoid receptor agonists and can antagonize Delta(9)-tetrahydrocannabinol in vivo.
为了通过确定合成的Δ⁹ - 四氢大麻二酚(O - 4394)和Δ⁸ - 四氢大麻二酚(O - 4395)在体内是否表现为CB₁受体拮抗剂,来跟进从大麻中提取的Δ⁹ - 四氢大麻二酚(eΔ⁹ - THCV)是CB₁受体拮抗剂的体外证据。
将O - 4394和O - 4395与eΔ⁹ - THCV作为从小鼠脑膜上特异性CB₁结合位点置换[³H] - CP55940的置换剂进行比较,并在使用小鼠脑膜进行的[³⁵S]GTPγS结合试验中作为CP55940的拮抗剂以及在小鼠离体输精管中作为R-(+)-WIN55212的拮抗剂进行比较。然后研究它们拮抗3或10 mg kg⁻¹(静脉注射)Δ⁹ - 四氢大麻酚对小鼠体内作用的能力。
O - 4394和O - 4395作为[³H] - CP55940的置换剂(Ki分别为46.6和64.4 nM)以及在[³⁵S]GTPγS结合试验中作为CP55940的拮抗剂(表观KB分别为82.1和125.9 nM)和在输精管中作为R-(+)-WIN55212的拮抗剂(表观KB分别为4.8和3.9 nM)时,表现出与eΔ⁹ - THCV相似的效力。静脉注射剂量为0.1、0.3、1.0和/或3 mg kg⁻¹时,O - 4394和O - 4395减弱了Δ⁹ - 四氢大麻酚诱导的抗伤害感受(甩尾试验)和体温过低(直肠温度)。O - 4395而非O - 4394也拮抗了Δ⁹ - 四氢大麻酚诱导的环僵。单独使用时,O - 4395和O - 4394在3或10 mg kg⁻¹(静脉注射)时诱导环僵,在剂量高于10 mg kg⁻¹(静脉注射)时诱导抗伤害感受。O - 4395在3 mg kg⁻¹(静脉注射)及以上剂量时也诱导体温过低。
O - 4394和O - 4395作为CB₁受体配体以及大麻素受体激动剂的拮抗剂,在体外表现出与eΔ⁹ - THCV相似的效力,并且可以在体内拮抗Δ⁹ - 四氢大麻酚。